Explorez tous les épisodes du podcast EASL Podcasts

Hepatocellular carcinoma (HCC) surveillance is a cornerstone of liver disease management, yet uncertainty persists around who to screen, when to initiate surveillance, and which modalities to use. Evolving risk profiles and variation across guidelines have added complexity to clinical decision-making. In this podcast, we revisit the fundamentals of HCC screening, focusing on practical, evidence-based approaches to patient selection, timing, and surveillance strategies.

Host: Mattias Mandorfer (Medical University of Vienna)
Guests: Peter Jepsen (Aarhus University), Amit Singal (UT Southwestern Medical Center)

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-20

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-20).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

This episode explores psychohepatology, examining the gut–liver–brain axis and the bidirectional links between liver disease and mental health. Discussion covers addiction biology, the impact of trauma and post-traumatic stress disorder (PTSD) on alcohol use, and the high prevalence of depression and anxiety in cirrhosis, highlighting integrated approaches to liver and mental health care. 

Host: Mads Israelsen (Odense University Hospital)
Guests: Nicola Kalk (South London and Maudsley NHS Foundation Trust), Victoria Kronsten (King's College London) 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-19

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-19).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

This EASL Deep Dive explores key updates from the EASL Clinical Practice Guidelines on hepatocellular carcinoma (HCC), with a practical focus on diagnosis and treatment selection. Experts will discuss evolving imaging and diagnostic criteria, patient selection for surgery and locoregional therapies, and how to adapt management according to response to systemic treatment. The session will also highlight the growing importance of multidisciplinary, individualised care across the HCC treatment pathway.

This episode of Talk Liver to Me explores the practical use of resmetirom and semaglutide in MASH, based on the 2026 EASL–EASD–EASO Guidance. Experts discuss who may benefit from treatment, when to initiate therapy, and how to monitor response and efficacy in clinical practice. 

Host:  Debbie Shawcross (EASL)
Guests:  Andreea Ciudin (EASO), Amalia Gastaldelli (EASD), Frank Tacke (EASL) 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-18

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-18).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

Liver disease represents a major and under-recognised public health challenge across Africa, driven by a complex interplay of viral hepatitis, rising metabolic dysfunction-associated steatotic liver disease, and a high burden of hepatocellular carcinoma (HCC). Despite this, awareness, surveillance, and access to care remain limited. In this podcast, we explore the evolving epidemiology of liver disease across the continent, highlighting key drivers, regional variations, and gaps in diagnosis and treatment. Why does the burden remain so under-recognised, and what are the priorities for prevention, early detection, and equitable care in Africa?

Host: Debbie Shawcross (King's College London)
Guests: Kwame Asomoah (University of Ghana Business School) and Wendy Spearman (University of Cape Town) 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-17

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-17).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

This webinar explores the role of genetic testing in diagnosing Progressive Familial Intrahepatic Cholestasis (PFIC). Attendees will review key test types, understand the principles behind modern genomic technologies, and learn how to position these tests in the diagnostic approach of a person with a suspicion of PFIC and how to navigate common challenges in interpreting genetic results. The session will also highlight emerging trends shaping the future of genetic diagnostics in hepatology. 

Learning objectives 

• Understand the genetic drivers of PFIC and the utility of their testing. 
• Describe basic principles behind modern diagnostic genetic testing relevant to hepatology. 
• Appropriately position genetic testing in the approach of a person suspected to have PFIC. 
• Recognize common challenges in interpreting these genetic findings and linking them with the clinical presentation. 
• Outline emerging trends influencing the future of genetic diagnostics in hepatology

This webinar has received educational grants from IPSEN. IPSEN has had no input into the programme, content, or faculty selection.

Acute liver failure (ALF) is a rare but life-threatening condition requiring rapid recognition and decisive management. Early decisions around investigation, escalation, and referral can significantly impact outcomes. Despite advances in care, variation in practice and avoidable pitfalls remain common. In this podcast, we take a practical, case-based approach to the key “dos and don’ts” in ALF management, focusing on early diagnosis, initial stabilisation, appropriate investigations, and timely referral to specialist centres. What should clinicians prioritise, what should be avoided, and how can we optimise care in the critical early stages of acute liver failure?

Host: Mattias Mandorfer (Medical University of Vienna)
Guests: William Bernal (King's College London), Nigel Heaton (King's College London) 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-16

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-16).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

Endohepatology is emerging as a novel approach to liver disease assessment, with the potential to combine EUS-guided liver biopsy, portal pressure measurement, and variceal evaluation within a single session. This “one-stop shop” model could streamline diagnostic pathways and enable integrated, real-time clinical decision-making. However, this innovation comes at a time when hepatology is moving increasingly towards non-invasive testing strategies. Questions therefore remain around its appropriateness, clinical utility, and feasibility in routine practice. In this podcast, we explore whether this approach represents meaningful progress or premature adoption, examining current evidence, potential benefits, and practical challenges. 

This episode is produced in collaboration with the European Society of Gastrointestinal Endoscopy (ESGE).

Host:  Tom Marjot (King's College London)
Guests:  Juan Abraldes (University of Alberta), Hannah van Malenstein (University Hospital Leuven) 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-15

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-15).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

Early-career researchers and clinician-scientists play a central role in advancing hepatology research and innovation, yet the transition to independence often comes with challenges that extend beyond scientific expertise. Building a research programme, leading teams, securing funding, and developing a sustainable academic career require skills that are rarely addressed during formal training. In this podcast, we explore the realities of early academic leadership, focusing on the practical and professional challenges faced during the first years of research independence. 

Host: Carolin Schneider (RWTH Aachen University)
Guests: Pierre-Emmanuel Rautou (Hôpital Beaujon, APHP & Université Paris Cité), Mathias Heikenwälder (University of Tübingen)

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-14

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-14).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

Hepatitis E is a globally prevalent infection with diverse clinical manifestations, ranging from self-limiting acute hepatitis to chronic infection in immunosuppressed patients. Its presentation and epidemiology vary significantly between regions, influencing diagnostic and management strategies. Despite increasing recognition, uncertainty remains around who to test, when to treat, and how to manage chronic disease effectively. In this podcast, we bring together perspectives from Europe and Asia to explore key differences in clinical practice, emerging evidence, and practical approaches to care.

Host: Thomas Marjot (Kings College London)

Guests: Tobias Böttler (Universitätsklinikum Freiburg), Siddharth Sridhar (University of Hong Kong)

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-13

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-13).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

Metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure with preserved ejection fraction (HFpEF) are increasingly recognised as manifestations of a shared cardiometabolic disorder. Driven by overlapping risk factors such as obesity and insulin resistance, these conditions frequently coexist and may interact through liver–heart crosstalk. Despite this, they are typically managed separately, with limited disease-specific therapies and suboptimal outcomes. In this podcast, we explore whether a more integrated approach could improve diagnosis, risk stratification, and treatment. 

Host: Cyrielle Caussy (Lyon 1 University and Hospices Civils de Lyon)

Guests: Zannad Faiez (University of Lorraine, Nancy), Pinelopi Manousou (Imperial College London)

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-12

Talk Liver To Me is supported by Opella. Opella has had no input to the content of this programme.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-12).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

The following objectives will be addressed in this EASL Deep Dive episode:

• Have a profound knowledge of the pitfalls, limitations and difficulty of interpretation of the different tests of copper metabolism and liver copper assessments
• Be able to establish a diagnostic approach to Wilson’s disease, integrating clinical, laboratory, genetic and imaging tools
• Have a good understanding of the different treatment modalities, how to position them in the disease course, how to monitor treatment and what to expect as a result/outcome?

This EASL DeepDive webinar is supported by Orphalan and Univar Solutions. Orphalan and Univar Solutions have had no input into the content of this EASL DeepDive.

Steatotic liver disease (SLD) research relies heavily on preclinical models, yet no single model can fully capture the complexity of human disease. In this episode, we explore the new EASL position paper on preclinical SLD models. From MASLD and MetALD to organoids and precision-cut liver slices, we discuss the strengths, limitations, and translational relevance of today's most widely used models. How do we choose the right model, and are we any closer to finding the perfect one?

Based on EASL position paper on preclinical models of steatotic liver disease

Host: Rui Castro (University of Lisbon) 
Speakers: Mathias Heikenwälder (University of Tübingen) and Suchira Gallage (University of Tübingen)

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-11

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-11).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

Haemochromatosis remains one of the most common inherited metabolic disorders, yet it is frequently underdiagnosed and inconsistently managed in clinical practice. With widespread use of iron studies and genetic testing, clinicians are increasingly faced with questions around interpretation, penetrance, and clinical significance. In this podcast, we explore current challenges in diagnosis and management, focusing on who should be tested, how to interpret results, and which patients benefit from intervention in modern hepatology practice. 

Host: Thomas Marjot (King's College, London)
Speakers: John Ryan (Beaumont Hospital, Dublin) and Heinz Zoller (Medical University of Innsbruck)

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-10

In this episode, we discuss the first pig-to-human liver xenotransplantation and the breakthroughs behind the revival of xenotransplantation, examining its potential and remaining challenges. We also explore the accelerating field of machine perfusion, clarifying different approaches and reviewing the evidence supporting their role in organ assessment, optimisation, and DCD utilisation.

Host: Sarwa Darwish Murad (Erasmus University Rotterdam)
Speakers: Jeroen de Jonge (Erasmus University Rotterdam) and Matthew Armstrong (University Hospital Birmingham)

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-09

Spontaneous bacterial peritonitis (SBP) remains a major complication of cirrhosis - but rising antimicrobial resistance and emerging data are challenging long-standing practices.

In this episode, we review current evidence on primary and secondary prophylaxis, resistance patterns, albumin use, and treatment strategies. How should clinicians balance prevention with antimicrobial stewardship? And where might practice need to evolve in 2026?

Host: Thomas Marjot (King's College London)
Speakers:  Bogdan Procopet (Institute of Gastroenterology and Hepatology, Cluj-Napoca) and Alastair O'Brien (Royal Free Hospital, London) 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-08

In this EASL DeepDive webinar, the expert panel presents and explains the key studies behind the latest recommendations included in the EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma.

Learning Objectives

• To identify patients at risk for eCCA, and review the current tools and strategies for its surveillance, diagnosis, staging, and classification
• To define the optimal candidates for resection and liver transplantation, and discuss challenges in the surgical management of eCCA
• To discuss the role of systemic therapy in the management of eCCA across all disease stages (including neoadjuvant, adjuvant, and palliative settings)

Faculty

• Luca Maroni - Moderator
• Julie Heimbach - Speaker
• Anna Saborowski - Speaker
• Lars Aabakken - Speaker

This episode explores the role of lifestyle in preventing and managing liver disease, including MASLD/MASH. Our experts discuss the impact of diet and physical activity, why lifestyle change can be difficult to start and sustain, and why small, achievable steps can still make a meaningful difference. 

Host: Cyrielle Caussy
Speakers:  Kate Hallsworth and Manuel Romero-Gómez 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-07

In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of hepatitis B virus infection, published in the "Journal of Hepatology" in 2025.

Learning objectives

• Understand the updated EASL recommendations for initiating and discontinuing antiviral therapy in chronic hepatitis B, including key differences with other HBV guidelines. Participants will be able to identify treatment indications and make informed decisions about when and how to stop antiviral therapy.
• Learn how to monitor patients with hepatitis B across different clinical scenarios, including those not on treatment, those receiving antiviral therapy, surveillance for hepatocellular carcinoma, risk of reactivation, and response to vaccination, in alignment with the new EASL guidelines.
• Explore future directions in the management of chronic hepatitis B as outlined in the EASL guidelines, including advances in nomenclature and antiviral therapies under development.

Faculty

• Markus Cornberg - Moderator
• Maud Lemoine - Speaker
• Sabela Lens - Speaker
• Jerzy Jaroszewicz - Speaker

Hepatocellular carcinoma (HCC) is responsible for 75% of all primary liver cancers and is the third most prevalent cause of cancer death worldwide, with 900,000 new cases diagnosed each year. Many patients are diagnosed at an advanced stage, making curative treatment difficult.

In this DeepDive Webinar, you’ll be guided through the latest advances in hepatocellular carcinoma management, from the rising impact of immunotherapy combinations to evolving approaches in intermediate-stage disease. 

This EASL DeepDive webinar is supported by Bayer AG. Bayer AG has had no input into the content of this EASL DeepDive.

Learning Objectives

• What are strategies to optimise surveillance and early diagnosis of hepatocellular carcinoma
• What are the optimal candidates for surgery (including liver transplantation) and locoregional therapies (alone or combined with immunotherapy)
• Optimal selection of systemic front-line regimens and treatment sequencing after first-line immunotherapy

Faculty

• Manon Allaire - Moderator
• Fabio Piscaglia - Speaker
• Antonio D'Alessio - Speaker
• Anna Saborowski - Speaker

In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of autoimmune hepatitis, published in the "Journal of Hepatology" in 2025.

Learning objectives

• Select induction and maintenance treatment strategies aimed at achieving complete biochemical response
• Recognise and manage disease flares, treatment intolerance, and suboptimal response in autoimmune hepatitis
• Understand tailored approaches to autoimmune hepatitis management in specific patient groups

Faculty

• Mária Papp - Moderator
• Michael Heneghan - Speaker
• George Dalekos - Speaker
• Maria Carlota Londoño - Speaker

In this episode our speakers share their immediate impressions and break down the key highlights shaping the management of portal hypertension and advanced liver disease. What has truly changed in practice? Where was consensus reached and where do controversies remain?

Tune in for a clear, practical overview of what you need to know from Baveno VIII.

Host: Thomas Marjot
Speakers:  Mattias Mandorfer and Cristina Ripoll

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-06

This episode unpacks the updated BCLC guidelines for hepatocellular carcinoma management. Experts discuss the strengths and limitations of the BCLC model in an era of rapidly evolving systemic therapies and personalised care, sharing real-world examples of when the algorithm helps and when clinical practice diverges.

Host: Mattias Mandorfer
Speakers:  Marco Sanduzzi, Lorenza Rimassa

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-05

As deaths from advanced chronic liver disease rise, many patients never receive timely palliative care.

In this episode, we explore why early, holistic support is essential in advanced liver disease and HCC, and unpack key recommendations from the new EASL Position Paper to help reduce suffering and improve quality of life.

Host:  Debbie Shawcross
Speakers: Patrizia-Künzler-Heule, Sumita Verma 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-04

This episode explores whether MetALD is a meaningful clinical entity or an unnecessary complication. Experts discuss the overlap between metabolic dysfunction and alcohol use, the challenges of applying the MetALD definition in practice, and its impact on classification, guidelines, drug development, and patient care. 

Host:  Thomas Marjot
Speakers:  Mary Rinella ,  Aleksander Krag 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-03

EASL’s Secretary General and Vice Secretary General share an open conversation on the challenges and opportunities for women in hepatology. The episode explores the role of mentorship across career stages and reflects on the journey toward EASL’s first female Secretary General, offering insights on leadership and change in the field.

Host: Maja Thiele
Speakers: Debbie Shawcross, Ana Lleo

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-02

In collaboration with the Indian National Association for the Study of the Liver (INASL), hepatologists from South Asia and North America/Europe take listeners inside their liver wards to explore how regional context shapes acute liver care. From admission patterns to alcohol use, infections, DILI, nutrition, and access to transplant, the episode highlights key differences and opportunities for shared learning across regions.

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-01

This EASL Studio episode brings key insights from the 2025 EASL–AASLD Consensus Conference on Primary Biliary Cholangitis (PBC).

Experts explore the use of surrogate endpoints, the challenges in current trial design and regulation, the value of real-world evidence, and how quality-of-life assessment can support future pathways.

Moderator: David Jones

Speakers: Marco Carbone, Bettina Hansen, and Ana Lleo

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

How can we protect young adults from steatotic liver disease (SLD)? This episode explores the burden of MASLD, MetALD, and ALD in Europe, the synergistic effects of alcohol and metabolic risk factors, and why the younger population is especially vulnerable. Experts also examine the disparities in risk factors and the role of clinics and policymakers in prevention.

Moderator: Shira Zelber Sagi

Speakers: Carina Ferreira-Borges (WHO representative) and Zobair Younossi

This EASL Studio is supported by Opella. EASL has received no input from Opella with regards to the content of this programme.

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

What were the key takeaways from this year’s AASLD The Liver Meeting? In this episode, experts unpack the most impactful studies, clinical insights, and emerging trends shaping the future of hepatology. From liver cancer breakthroughs to MASLD, ALD, and beyond.

Moderator: Debbie Shawcross

Speakers: Saul Karpen, Allison Kwong, Mazen Noureddin

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

For World Antimicrobial Awareness Week 2025 (“Act Now: Protect Our Present, Secure Our Future”), this EASL Studio explores the balance between rifaximin’s benefits in hepatic encephalopathy and the global challenge of antimicrobial resistance.

Moderator: Debbie Shawcross

Speakers: Rajiv Jalan, Vishal Patel, Jonel Trebicka

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

This EASL Studio is supported by Alfasigma and Norgine. EASL has received no input from Alfasigma or Norgine with regards to the content of this programme.

Ever wondered what happens to your manuscript after submission? In this episode, the JHEP Reports editorial team takes you behind the scenes: from first triage to reviewer selection, smart moves vs. red flags, and how final decisions are made. The discussion also explores the potential, limitations, and ethical pitfalls.

Moderator: Mattias Mandorfer 

Speakers: Tobias Böttler, Virginia Hernández-Gea, Josep Llovet

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

After years of limited progress, recent trials hint at a changing landscape for primary sclerosing cholangitis (PSC). In this episode, experts review emerging data and explore whether we’re approaching a new era of effective treatment. How should clinicians assess these therapies, and could they shift the current management of PSC?

Moderator: Debbie Shawcross

Speakers: Cynthia Levy, Stephen Rossi, Michael Trauner

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

This episode questions whether assigning the label “ACLF” to a deteriorating patient truly alters clinical decisions, or if focusing on the specifics of organ failure and reversibility is more useful. Experts debate the real-world utility of prognostic scores, the clarity (or confusion) created by multiple definitions, and whether the ACLF concept drives urgency, facilitates transplant access, or improves outcomes. A thought-provoking look at where terminology meets bedside care.

Moderator: Tom Marjot 

Speakers: Paolo Angeli and Julia Wendon

This EASL Studio is supported by GENFIT. EASL has received no input from GENFIT with regards to the content of this programme. 

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

This EASL Studio explores the discrepancy between the huge burden of patients hospitalised with, and dying from, alcohol-related liver disease (ALD) or MetALD, versus the same disease’s near non-existence from population data. The panel will discuss whether current classification systems (heavily favoring metabolic causes) misrepresent the true burden of ALD and MetALD, and what clinicians can do to better map the role of alcohol in liver patients.

Moderator: Maja Thiele

Speakers: Brian Lee, Mzamo Mbelle, Elisa Pose

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

What do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025?

Moderator: Ahmed Elsharkawy

Speakers: Ashley Brown, Tatyana Kushner and Sabela Lens

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

In hepatology, effective care goes beyond diagnostics and treatment. This episode explores the crucial questions hepatologists should ask to truly understand their patients’ needs, values, and priorities. By focusing on communication and patient-centred care, our experts highlight how listening carefully can improve adherence, enhance quality of life, and ultimately lead to better outcomes.

Moderator: Pierre-Emmanuel Rautou

Speakers: Agnès Dumas, Maria Hjorth, José Willemse, Zobair Younossi

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

This first session in a two-part EASL DeepDive series on the 2024 EASL-EASD-EASO MASLD Clinical Practice Guidelines will provide a detailed examination of the recommendations concerning diagnosis, non-invasive assessment, and risk stratification, with a view to supporting evidence-based clinical practice.

Learning objectives

• Have a good understanding of the concept/definition of MASLD within the framework of the new SLD nomenclature, including its contribution to disease progression in other diseases
• Get familiar with the role of non-invasive tests for risk stratification in MASLD, their pro- and cons, and how and in whom to use them for screening/case finding
• Get a detailed understanding of HCC risk and risk stratification in MASLD and the surveillance strategies to implement

This programme is part of the EASL Guidelines Implementation Programme on MASLD supported by Boehringer Ingelheim and Novo Nordisk. Boehringer Ingelheim and Novo Nordisk have had no input in the selection and creation of this programme.

This episode addresses key challenges in vascular complications of liver disease, including the management of portal vein thrombosis (PVT) in patients with and without cirrhosis. Experts will explore controversies surrounding long-term anticoagulation therapy and discuss insights from the CIRROXABAN paper. Additionally, the episode will shed light on the management of splanchnic artery aneurysms, offering valuable guidance for clinical practice.

Moderator:  Pierre-Emmanuel Rautou;

Faculty: Sarwa Darwish Murad, Juan-Carlos Garcia-Pagan, Valérie Vilgrain 

Related episodes

• S4E11 – YI Choice: Gene therapy for liver disease — RNA interference and beyond
• S4E6 – Regenerating the liver graft with a machine?
• S3E11 – Regenerative Hepatology: From stem cells to tissue engineering
• S2E9 – YI Choice: Propelling liver cell biology into the third dimension

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

In this new edition of the EASL DeepDive, expert faculty guide participants through a focused and forward-looking discussion on key aspects of advanced MASLD, setting the stage for a deeper understanding of evolving clinical challenges and opportunities.

This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive.

Learning objectives

• Understand the Pathophysiology: Describe the key pathophysiological mechanisms of MASLD and its progression to advanced liver disease and portal hypertension.
• Identify Unmet Clinical Needs: Recognise the current gaps in diagnosis, management, and treatment of advanced MASLD, highlighting the challenges of healthcare professionals in clinical practice.
• Evaluate Valuable Endpoints: Discuss the importance of selecting and utilising valuable clinical endpoints in managing MASLD to improve patient outcomes.
• Explore Emerging Therapies: Review the latest therapeutic strategies and potential interventions for advanced MASLD, focusing on how they address the unmet needs in patient care.

All EASL DeepDive are available on EASL Campus.

This EASL Studio episode explores state-of-the-art practices in diagnosing steatotic liver disease and stratifying patients effectively for targeted treatment in 2025. Focusing on integrating cardiometabolic risk profiling and dynamic alcohol consumption assessment, the discussion will discuss contemporary methods, frequency, and practical implementation in clinical settings to enhance precision medicine approaches.

Moderator: Aleksander Krag 

Faculty: Meena Bansal, Mattias Ekstedt, Arun Sanyal 

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

Listen to this EASL Studio episode to explore how artificial intelligence (AI) is transforming healthcare. Discuss its potential to revolutionise medical practice, its limitations, and whether it poses a threat or an opportunity for the future of the medical profession.

Moderator: Ahmed Elsharkawy  

Faculty: Jakob Kather, Sabela Lens, Ashley Spann 

Related episodes:

• EASL Studio at EASL Congress 2024 – Exploring new frontiers: The AI liver taskforce initiative
• S4E5 – AI for dummies
• S2E13 – Digital Pathology

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

With the release of the new HBV guidelines, treatment eligibility broadens. This EASL Studio explores how to communicate these changes, support shared decision-making, ensure adherence, and engage patients in ongoing care and clinical trials.

Moderator: Ahmed Elsharkawy 

Faculty: Markus Cornberg, Sital Shah, Thomas Tu, Su Wang

This EASL Studio is supported by Aligos Therapeutics, GSK and Gilead Sciences Europe Ltd . EASL has received no input from Aligos Therapeutics, GSK or Gilead Sciences Europe Ltd with regards to the content of this programme.

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

Listen to this EASL Studio episode for insights on the new MASLD guidelines and their practical application. Hear from experts on navigating the nomenclature change, implementing guidelines in clinical workflows, and fostering behavioral change to improve patient outcomes across the care team.

Moderator: Sven Francque 

Faculty: Marta Cervera, Elena George, Shelley Keating

This programme is part of the EASL Guidelines Implementation Programme on MASLD supported by Boehringer Ingelheim and Madrigal Pharmaceuticals. Boehringer Ingelheim or Madrigal Pharmaceuticals have had no input in the selection and creation of this programme.

Related episode

• S5E5 – JHEP Live: The new nomenclature for SLD: A multidisciplinary evaluation and approach

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

This EASL Studio episode cuts through the noise to explore alcohol’s true impact on health and society, spotlighting patient stories, public misconceptions, and bold policy solutions from across Europe.

Moderator: David Barret (Internal Communications and Multimedia Manager, WHO Regional Office for Europe)

Faculty: Carina Ferreira-Borges (Regional Advisor for Alcohol, Illicit drugs and Prison health, WHO Regional Office for Europe), Aleksander Krag (EASL Secretary General), Hazel Martin (BBC Journalist and Liver Patient), Margarida Santos (General Practitioner Portugal), Riina Sikkut (Member of Estonian Parliament, former Minister of Health of Estonia)

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

What happens when hepatologists and interventional radiologists join forces? This episode discusses the power of collaboration – shared guidelines, joint training, and multidisciplinary care – to improve outcomes in complex liver disease.

Moderator: Sven Francque

Faculty: Irene Bargellini, Virginia Hernández-Gea, Max Seidensticker

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

Listen to this episode for a curated overview of landmark studies and breakthrough data presented at EASL Congress 2025, with expert insights on their clinical relevance and impact on the future of hepatology.

Moderator: Thomas Berg 

Faculty: Hannes Hagström, Verena Keitel, Raj Mookerjee

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

Most liver diseases are diagnosed when it’s already too late. This episode explores the pros and cons of early screening, the gaps in current strategies, and how projects like LIVERAiM are aiming to change the game.

Moderator: Ahmed Elsharkawy

Faculty: Pere Ginès, Ian Rowe, Maja Thiele

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

In this fifth edition of the EASL DeepDive, join Christophe Bureau, Virginia Hernandez-Gea, Marika Rudler, and Manhal Izzy to gain expert insight into the selection, management, and outcomes of patients undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures.

This EASL DeepDive webinar is supported by W. L. Gore & Associates. W. L. Gore & Associates has had no input into the content of this EASL DeepDive.

Learning objectives

• Understand the criteria for selecting appropriate patients for Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures
• Learn to differentiate between high-risk and low-risk patients based on clinical indicators and patient history
• Explore the impact of cardiopulmonary conditions on the outcomes of TIPS procedures, and how/when to monitor for new-onset heart failure post TIPS
• Learn from Marika Rudler about the strategies for preventing and managing post-TIPS hepatic encephalopathy (HE)
• Discuss the latest research and treatments available for managing EH in TIPS patients

All EASL DeepDive are available on EASL Campus.

This EASL Studio episode discusses cutting-edge approaches for managing bleeding varices. Explore the evolution of endoscopic therapies, the role of interventional radiology, and decision-making for high-risk gastric varices. Gain insights into EUS-guided portal pressure assessment and its impact on tailoring treatment strategies.

Moderator: Debbie Shawcross

Faculty: Wim Laleman, David Patch

Related episode

• S6E14: Endohepatology: The endoscopic liver gold rush

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.